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in­Hungary,­limited­amount­of­published­data­exist­on­real-life­
setting­clinical­outcome,­treatment­compliance­and­tolerabi-
lity­of­adalimumab­therapy.­
EviraEast,­a­multi-country­post­marketing­observational­study­
assessed­clinical­outcomes­of­adalimumab­treatment­in­adult­
patients­ with­ active­ rheumatoid­ arthritis,­ psoriatic­ arthritis­
and­ankylosing­spondylitis­during­a­13-month­follow-up.­
in­ Hungary,­ 315­ patients­ were­ enrolled;­ the­ mean­ duration­
of­disease­at­baseline­was­8.0­years,­and­the­majority­of­RA­
and­AS­patients­had­high­disease­activity­ (dAS28>5.1).­The­
mean­duration­of­adalimumab­treatment­was­48.0­weeks­with­
23.2%­dropout­rate.­High­compliance­rate­(93.6%)­was­obser-
ved­and­the­majority­(93.6%)­of­patients­accepted­self-injec-
tion.­Positive­clinical­outcome­(decrease­of­dAS28≥1.2)­at­3­
months­was­achieved­by­more­ than­50%­of­patients.­At­ the­
end­of­ study,­ remission­ (dAS28<2.6)­ rate­ in­RA­was­34.3%,­
whilst­BASdAi­50­response­rates­were­observed­68.5%­of­AS­
and­76.9%­of­PsA­patients.­improved­physical­function­in­and­
good­tolerability­with­adalimumab­therapy­was­documented.­
overall­adverse­event­rate­was­18.2%.­
The­results­confirmed­well­established­effectiveness­and­sa-
fety­profile­of­adalimumab­in­routine­clinical­practice­ in­the­
approved­rheumatic­indications.­
kEyWoRdS:­ Adalimumab,­ Psoriatic­ arthritis,­ Rheumatoid­
arthritis,­Ankylosing­spondylitis,­Effectiveness,­observational
AZ­ AdALiMuMABBAL­ kEZELT­ RHEuMAToid­ ARTHRiTi-
SES,­ ­ARTHRiTiS­ PSoRiATiCáS­ éS­ SPondyLiTiS­ AnkyLo-
PoETiCáS­ BETEGEk­ kLinikAi­ EREdMényEinEk,­ A­ BETEGEk­
EGyüTTMűködéSénEk­ éS­ A­ GyóGySZER­ ToLERáLHATóSá-
GánAk­ ViZSGáLATA­ MAGyARoRSZáGon:­ EviraEast,­ TöBB­
­oRSZáGBAn­ VéGZETT­ MuLTiCEnTRikuS­ PoSZTMARkETinG,­
MEGFiGyELéSEn­ALAPuLó­ViZSGáLAT
Magyarországon­kevés­publikált­adat­áll­rendelkezésre­a­va-
lós­életből­az­adalimumab-terápia­klinikai­ eredményeivel,­ a­
betegegyüttműködéssel­és­tolerálhatósággal­kapcsolatban.
Az­EviraEast­13­hónapos­utánkövetéses­posztmarketing,­több­
országra­kiterjedő,­multicentrikus,­megfigyelésen­alapuló­vizs-
gálat,­mely­felnőtt,­aktív­rheumatoid­arthritises­(RA),­arthritis­
psoriaticás­(PsA)­és­spondylitis­ankylopoeticás­(SPA)­betegek­
klinikai­eredményeit­vizsgálta­adalimumab-terápiát­követően.
Magyarországon­315­beteg­vett­részt­a­vizsgálatban,­indulás-
kor­a­betegség­fennállásának­átlagos­időtartama­8,0­év­volt,­
és­ a­RA-es­ és­ a­SPA-s­betegek­ többségének­magas­aktivi-
tású­volt­ a­betegsége­ (dAS28>5,1).­Az­adalimumab-kezelés­
átlagos­ időtartama­ 48­ hét­ volt,­ 23,2%-os­ lemorzsolódással.­
A betegegyüttműködési­arány­magas­volt­(93,6%),­és­a­bete-
gek­többsége­(93,6%)­elfogadta­az­öninjekciózást.­A­betegek­
több­mint­50%-ánál­3­hónap­után­klinikai­javulás­(dAS28>1,2­
csökkenése)­volt­megfigyelhető.­A­vizsgálat­végén­a­remisz-
szió­(dAS28<2,6)­aránya­34,3%­volt­RA-ben,­míg­a­BASdAi­50­
válaszaránya­68,5%­volt­SPA-ban­és­76,9%­PsA-ban.­Az­adali-
mumab-terápia­jól­tolerálható­volt­és­fizikai­funkciójavulást­is­
dokumentáltak.­A­nem­kívánt­reakciók­aránya­összességében­
18,2%­volt.
Az­eredmények­igazolták,­hogy­az­engedélyezett­reumatoló-
giai­indikációkban­az­adalimumab­a­rutin­klinikai­gyakorlat-
ban­megalapozoott­hatékonysággal,­és­biztonságossági­pro-
fillal­rendelkezik.
kuLCSSZAVAk:­adalimumab,­arthritis­psoriatica,­ rheumatoid­
arthritis,­spondylitis­ankylopoetica,­hatékonyság,­megfigyelé-
sen­alapuló
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Introduction
Inflammatory rheumatic disorders such as rheu-
matoid arthritis (RA), ankylosing spondylitis (AS) 
and psoriatic arthritis (PsA) carry significant disease 
burden requiring effective medical interventions and 
treatment strategies. 
RA is characterized as a progressive inflammatory 
synovitis with joint swelling affecting approximately 
1% of the adult population. As the disease progress-
es structural joint damage develops and joint func-
tion deteriorates. In RA, joint damage and physical 
disability are the major adverse outcomes associated 
with reduction in quality of life and premature mortal-
ity. PsA is a heterogeneous condition with prevalence 
of 0.1%, characterized by its broad spectrum of phe-
notypes of joint involvement, skin and extra-articular 
manifestations involving multiple organs. PsA can 
develop at any time, but for most people, it appears 
between the ages of 30 and 50, affecting men and 
women equally [1]. Left untreated, PsA can be a pro-
gressively disabling disease. AS is a chronic inflam-
matory rheumatic disease with a prevalence of 0.2%. 
AS mostly affects the spine and sacro-iliac (SI) joints 
but it is also frequently accompanied with peripheral 
and extraarticular manifestations [2]. AS can cause 
pain and limited range of motion in the lower back, 
hips or neck. Fatigue and continuous pain are debili-
tating, and decrease the quality of life. The inflamma-
tion is frequently accompanied with ankylosis which 
might cause the joints and bones to fuse causing 
deformity and disability [3]. Biologic response modi-
fiers like tumor necrosis factor (TNF) inhibitors have 
become established therapies for active RA, AS and 
PsA in recent years in Hungary.
In many areas of medicine, such as diabetes care 
or cardiology, clear therapeutic targets are available. 
More recently, in 2010, a treatment target has also 
been advocated for RA, namely remission or low dis-
ease activity. This recommendation is based on data 
from various clinical trials showing a good correlation 
with these clinical outcomes and long term functional 
improvement and damage progression control, as 
revealed by systematic literature reviews [4]. Much 
less information on the value of defining therapeutic 
targets for ankylosing spondylitis or psoriatic arthritis 
was available until 2013. 
Recently, an international task force was set forth 
with the aim of improving management of RA in 
clinical practice, thus providing guidance for treat-
ment to target (‘T2T’). To achieve optimal therapeutic 
outcomes in RA, the treatment aim was defined as 
clinical remission, being disease activity an alternative 
goal in patients with long-standing disease. Regular 
follow-up (every 1-3 months during active disease) 
with appropriate therapeutic adjustment to reach the 
desired condition within 3 to a maximum of 6 months 
was recommended [4]. In Hungary, the most com-
monly used measure of remission is DAS28 score < 
2.6. However, the establishment of remission should 
not be based on a single time point measurement, 
but rather for a longer time-period to avoid disease 
progression during intercurrent phases of increased 
disease activity. Furthermore, radiological progres-
sion is currently not assessed routinely, but is the 
key to monitor long-term disability [5]. Recent data 
indicated that the level of remission as well as the 
length of being in remission affects subsequent pro-
gression of radiographic damage in RA. Long-term 
remission induced by intensive, short-term treatment 
selected by biomarker profiles is the ultimate goal in 
the management of RA [6]. In 2010, the same year 
as the ‘Treating rheumatoid arthritis to target’ con-
sensus paper was published, recommendations for 
the management of rheumatoid arthritis by EULAR 
also appeared in a separate paper [6]. The EULAR 
recommendations which have just been updated [24] 
complement with the ‘T2T’ outcomes in general prin-
ciples, but are more specific in providing guidance for 
the use of individual drugs or drug classes. 
T2T recommendations were also published for 
spondyloarthritis (SpA). In 2013, a task force was 
formed to discuss and develop a consensus on 
recommendations aimed at defining a treatment 
target for axial and peripheral SpA, thus improving 
the management these diseases in clinical practice 
[7]. Overarching principles and nine of the statements 
address SpA in general, and two more statements 
relate specifically to axial SpA, peripheral SpA and 
PsA. The main treatment target, which should be 
based on a shared decision with the patient, was 
defined as remission, or low disease activity as an 
alternative target for those patients who did not 
reach remission. Additional recommendations relate 
to extra-articular and extra-axial aspects and other 
important factors, such as comorbidity. T2T SpA 
recommendations can inform various stakeholders 
about expert opinion that aims for reaching optimal 
outcomes of SpA.
Treatment strategies of PsA have been changed 
significantly in the past few years, with emerging 
data demonstrating the benefits of conventional 
synthetic Disease Modifying Anti-Rheumatic Drugs 
(csDMARD) and tumor necrosis factor alpha (TNFα) 
inhibitors. EULAR recommendations have been 
recently developed to provide clinicians with concise, 
easy-to-follow guidance on optimal use of available 
therapies and with clear PsA treatment strategies 
[8]. Ten recommendations were developed for treat-
ment from NSAIDs through csDMARDs to biological 
agents, accounting for articular and extra-articular 
manifestations of PsA. The best evidence for efficacy 
is available for three csDMARDs (methotrexate, leflu-
nomide, and sulfasalazine) and four TNF inhibitors 
(adalimumab, etanercept, golimumab and infliximab). 
According to the 2010 EULAR recommendations, 
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TNF inhibitors should be considered in patients with 
active arthritis and an inadequate response to at least 
one csDMARD, such as methotrexate [8].
The key recommendations for axial SpA including 
AS are those recommended by ASAS/EULAR in 2010 
[9]. NSAIDs are first-line therapy for patients with axial 
SpA, and should be given continuously in patients 
with persistent active, symptomatic disease. Some 
evidence exists that continuous NSAID treatment 
may decrease radiographic progression; however, 
this finding is still controversial and NSAIDs also 
have significant side effects. csDMARDs, including 
methotrexate and sulfasalazine, are not effective 
in axial SpA and are not recommended for use in 
treatment of axial manifestations. ASAS recently 
published updated recommendations for anti-TNF 
use in AS, based on ASAS classification criteria 
[10]. The updated consensus for use of anti-TNFs 
recommends treatment with at least two NSAIDs 
over a 4-week period before use of anti-TNF agents. 
In axial SpA, therapy with an anti-TNF agent is 
recommended when therapy with NSAIDs have failed. 
Anti-TNFs improve the signs and symptoms of axial 
SpA, reduce disease activity, reduce inflammation in 
SI joints and spine, and improve health related quality 
of life. Recent evidence suggests that TNF inhibitors 
appear to reduce radiographic progression in AS, 
especially with early initiation and longer duration of 
follow up [11].The appropriate use of medication and 
treatment adherence are central to the successful 
management of long term conditions such as RA, 
PsA and AS as these are characterized by fluctuating 
and usually progressive disease courses and a need 
for lifetime medical management. Although biological 
DMARDs (bDMARDs) revolutionized the treatment 
of inflammatory rheumatic diseases, compliance 
with and adherence to these treatment modalities 
is a major issue like in other chronic diseases, since 
poor compliance to biologics can undermine the 
effectiveness of these expensive medications.
Adalimumab is a fully human anti-TNF monoclonal 
antibody with established efficacy and safety profile 
and indicated for the treatment of the above-
mentioned types of inflammatory arthritis [12]. In 
Hungary, limited amount of published data exist 
which characterize patient populations treated by 
adalimumab in SpA. Further, it is important to establish 
in real-life setting the clinical outcome and tolerability 
of adalimumab therapy in Hungarian patients, as well 
as their treatment compliance.
EviraEast was a non-interventional, post-mar-
keting, multi-country, multi-center, prospective, sin-
gle-arm, observational study conducted between 
2009 and 2011 in 6 Central and Eastern European 
countries including Hungary, and Israel. Of the 809 
patients enrolled in total, current analysis evaluates 
the results of patients from Hungary with main focus 
on achievement of treatment targets.
Methods
EviraEast (Evaluation of clinical outcome, treatment 
compliance and tolerability of HumIRA® (adalimumab) 
in patients with active Rheumatoid Arthritis, Psoriatic 
Arthritis and Ankylosing Spondylitis in EASTern 
European countries) aimed for assessing clinical 
outcomes, treatment compliance and tolerability of 
adalimumab in adult patients with active RA, PsA 
and AS during a maximum of 13-month follow-up. 
As a post-marketing observational study, EviraEast 
included patients that were eligible to adalimumab 
therapy according to the local product label 
and prescription/reimbursement guidelines. The 
investigational sites were medical centers experienced 
in biologic treatment. No additional procedures (other 
than standard of care) were applied to the patients. 
This study was conducted in accordance with 
requirements for monitoring, notification/submission 
of a post-marketing observational study of the 
Hungarian ethics committee and relevant regulations.
Patients
Adult patients with active RA, PsA (both with axial 
and peripheral symptoms) or AS were enrolled. The 
involved patients were either naive to adalimumab 
therapy (prior exposure to infliximab or etanercept 
treatment was allowed) or completed AbbVie spon-
sored interventional clinical trials and were continuing 
treatment with commercial adalimumab thereafter. 
The assignment of the patient to adalimumab was 
not decided in advance by this protocol as per the 
observational nature of the study, but fell within the 
current practice, and the prescription of adalimumab 
was clearly separated from the decision to include 
the patient in this study. Patients were excluded 
from the study if they were already treated (or were 
planned to be treated) with drugs of known interac-
tions with adalimumab, if they were participating in 
another clinical trial and if they had a diagnosis of 
active infection. Written informed consent for partici-
pation was obtained prior to enrolment in the study 
according to the Hungarian regulation. 
Study design and conduct
EviraEast was conducted in a prospective, single-
arm format. As this study was observational in 
nature, patients’ follow-up schedule was left to the 
judgment of their physicians within the 14–17 months 
period of the study (including latent tuberculosis 
(TB) screening and prophylaxis, if indicated). The TB 
screening period per patient was 1–4 weeks and, 
when required, the TB prophylactic treatment period 
before adalimumab administration was in accor-
dance with Hungarian guidelines [13]. According to 
the study protocol each patient was to be observed 
during his/her adalimumab treatment for a period of 
maximum 13 months. 
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The study duration allowed approximately 7 patient 
visits in the following recommended order: screening 
visit, followed by TB prophylaxis, if indicated; base-
line visit and introduction of adalimumab therapy; 
follow-up visit approx. 1 month after introduction of 
adalimumab therapy; subsequent follow-up visits 
approx. 3 months after the previous visit. The num-
ber and date of the visits were scheduled according 
to the decision of the physician so failure to meet 
the recommended dates did not constitute a breach 
of the protocol. If the physician decided to perma-
nently discontinue adalimumab before the end of 
the planned observational period of 13 months, the 
reason for discontinuation and the new treatment 
regimen prescribed, if applicable, was documented. 
The next routine follow-up visit was the termination 
visit for this patient. If treatment with adalimumab 
was discontinued, the physician was requested to 
see the patient after a period of 70 days or 5 half-lives 
following the administration of the last dose adalim-
umab treatment.
During the screening visit, the following patient 
characteristics and medical history data were doc-
umented: demographics and social background 
(education, profession), rheumatic disease: severity 
and duration, relevant medical history, including TB 
history and screening procedures for the presence 
of active or latent TB and TB prophylaxis (if appli-
cable). During Baseline visit, patients were intro-
duced to adalimumab therapy and baseline values 
were recorded. Throughout the Follow-up visits, 
disease specific treatment history (csDMARDs and 
bDMARDs) and current disease specific medications 
(csDMARDs, non-selective NSAIDS, cox-2 inhibitors, 
steroids) were recorded. DAS28 [14] for RA patients, 
BASDAI [15] for PsA and AS patients, HAQ-DI [16] 
and laboratory values (ESR or CRP) for all patients 
were also documented at each Follow-up visit. The 
date of patient training for self-injection of adalim-
umab was also documented. The main objectives 
during the follow-up visits were to evaluate the clinical 
outcome and tolerability of adalimumab treatment by 
tracking the change in DAS28 score for RA patients, 
BASDAI score for PsA and AS patients, HAQ-DI 
score and laboratory values (ESR, CRP). Patient 
acceptance of self-injection was evaluated based on 
the investigator’s opinion on the patient’s ability to 
appropriately execute self-injection after initial training 
in the medical center and documentation of neces-
sity of re-training. Compliance was evaluated based 
on injections missed or delayed by more than 7 days 
based on patients self-report. Changes in disease 
specific treatment were recorded at each visit.
Adverse events and serious adverse events were 
also recorded as per patient reports. Special atten-
tion was paid to opportunistic infections including 
TB, other serious infections, new malignancies, 
lupus/lupus-like syndrome, demyelinating disorders 
and congestive heart failure. Physicians rated the 
severity of any adverse event being collected as a 
data point in the study and for all serious adverse 
events as mild, moderate or severe. For serious 
adverse events, causality was also provided by the 
physician. Adverse events were coded according to 
MedDRA version 14.1, disease specific and prophy-
lactic tuberculosis treatments were coded according 
to  WHO-ATC English Version 2011.
Study endpoints
The primary endpoint for RA patients was the propor-
tion of patients with positive clinical outcome defined 
as a DAS28 decrease by 1.2 or more after 3 months 
of adalimumab treatment compared to baseline. 
For PsA and AS patients, the proportion of patients 
with 50% or higher decrease in BASDAI index after 
3 months of adalimumab treatment relative to base-
line served as primary endpoint (e.g. positive out-
come). Secondary end points were: mean HAQ-DI 
score decrease after 4, 7 and 13 months of adali-
mumab therapy compared to baseline; number and 
type of adverse events and serious adverse events; 
the duration of treatment with adalimumab; patient 
acceptability of self-injection (as detailed in section 
Study design and conduct).
Data processing and statistical analysis
The electronic data capture system webTrial (a.f.m. 
logic Völp, Göbel GbR) was utilized for data entry. All 
data have been entered into electronic case report 
forms (eCRFs). Case report forms were checked 
for consistency of data and inconsistent data were 
queried. Statistical analysis was performed by SAS® 
9.2 for Windows. 
The analysis of this observational study used 
only descriptive statistics, i.e. no statistical tests 
were performed. Qualitative data are presented 
by means of frequency distributions. For quantita-
tive data the number of analyzed values (n), mean, 
standard deviation (SD), minimum, 25% quartile, 
median, 75% quartile and maximum are provided. 
Generally no imputation of missing values was per-
formed. The time course of repeatedly measured 
parameters makes use of all available data assigned 
to the respective visit. In addition, a time point ‘end 
of study’ (EOS) was analyzed using the last observed 
value during the follow-up period (visits 3–7) and 
serves as ‘last-observation-carried-forward’ analysis. 
However, patient visits dated after the discontinua-
tion of adalimumab therapy were not analyzed. As 
a general principle, baseline values were defined as 
the assessments performed at Visit 2, irrespective of 
the start date of adalimumab therapy. The complete 
analysis was performed for each primary diagnosis of 
the rheumatic disease separately.
Discontinuation of adalimumab treatment and 
reason for discontinuation was also documented 
(with more than 1 discontinuation reason could be 
specified per patient).
Magyar Reumatológia, 2014, 55, 12–24.
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The incidence of adverse events (AE) and serious 
adverse events (SAEs) is presented, displaying the 
number and percentages of affected patients.
The use of anti-rheumatic medication history 
and concomitant anti-rheumatic treatment is also 
reported here. 
One major analysis dataset named statistical 
evaluation dataset (SES) was considered for the 
statistical analysis, which consisted of all patients 
whose primary diagnosis of rheumatic disease was 
specified and who were treated with adalimumab as 
it was documented on the eCRF. For the analysis of 
clinical outcome, a clinical outcome analysis dataset 
(COS) was utilized which included all patients of the 
SES, who had a non-missing assessment of clinical 
outcome at baseline and at least one follow-up visit 
(Visit 3–7) with an assessment of clinical outcome. In 
addition, patients with unclear visit schedules were 
also excluded from the COS.
Results 
In total, 809 patients were enrolled (440 patients/ 
54.4% with RA, 129 patients/15.9% with PsA and 
238 patients/29.4% with AS, 2 patients/0.2% with-
out primary diagnosis) in 6 different Eastern European 
countries (Croatia, Hungary, Poland, Romania, 
Slovakia, and Ukraine) and Israel. The first document-
ed study visit in Hungary was on April 2nd, 2009; the 
last documented visit of a patient took place on July 
15th, 2011. In Hungary, 315 patients were enrolled by 
72 investigators: 193 patients (61.3%) with RA, 39 
patients (12.7%) with PsA and 82 patients (26.0%) 
with AS. Out of these, 314 patients (99.6%) were 
evaluable for statistical analysis (statistical evalua-
tion set, SES). Furthermore, 252 patients of the SES 
(80.2%) were eligible for the primary analyses of clini-
cal outcome (COS, which includes all patients of the 
SES, who have a non-missing assessment of clinical 
outcome at baseline and not less than one follow-
up visit with a non-missing assessment of clinical 
outcome and in addition, patients with unclear visit 
schedules were also excluded from the COS). SES 
dataset was used for safety evaluations.
Investigational sites were 13 biological therapy cen-
ters in Budapest, Székesfehérvár, Debrecen, Kecske-
mét, Szeged, Gyula, Nyíregyháza, Szombathely, 
Veszprém, Miskolc, Pécs, Hévíz, Esztergom, the 
number of enrolled patients ranged from 2 to 92. 
The average duration of adalimumab therapy was 
48 weeks.
Patient characteristics are shown in Table I. The 
mean age in SES was 53.5, 50.1 and 45.5 years for 
RA, PsA and AS patients, respectively. The gender 
distribution was consistent with known demographic 
characteristics of the respective diseases: 84.5% of 
females among RA patients, 61.0% of males among 
AS patients, and almost balanced (48.7% of males 
and 51.3% of females) among PsA patients. As 
shown in Table I, positive result of latent TB screening 
was documented very rarely in the study population. 
In the following sections, efficacy data are ana-
lyzed and described by diagnostic groups.
Rheumatoid arthritis patients
The total number of RA patients enrolled in the 
study in Hungary was 193. Of those, 166 patients 
could be included into clinical outcome evaluation 
analyses. At the study end, the number of evalu-
able RA patients was 127 (65.8% of enrolled RA 
subjects), corresponding to a dropout rate of 34.2% 
throughout the study. Based on the observed data, 
the dropout started after the third visit. The mean 
age of RA patients was 53.5 (SD 12.0), the majority 
of them were female (Table I). The mean duration of 
RA at study start was 8.2 years. The percentages of 
patients with early disease (< 1 year from diagnosis) 
was low, only 4.1%. (It should be noted that diagno-
sis within 1 years of study start does not necessary 
mean an early disease.) Education level is depicted 
in Table I.
At baseline, 83.4% (n=161) of RA patients had 
high, 11.4% (n=22) moderate and 0.5% (n=1) low 
disease activity as indicated by the respective DAS28 
values (≥5.1, between 5.1 and 3.2 and <3.2). None 
of the patients were in remission at the beginning of 
the study. 
A patient could have more than one type of 
anti-rheumatic medication prior to and during adali-
mumab therapy. At baseline, 186 (96.4%) of the 
193 RA patients were on any kind of anti-rheumatic 
drug treatment. Most of the patients were being 
treated with csDMARDs (n=179; 92.7%), 79 (40.9%) 
with steroids and 34 (17.6%) with bDMARDs. The 
most commonly used csDMARDs were methotrex-
ate (n=153; 79.3%), sulfasalazine (n=86; 44.6%) and 
leflunomide (n=84, 43.5%). Almost half (46.1%) of 
RA patients received at least two csDMARDs prior 
to initiation of anti-TNF treatments, in line with local 
prescribing guidelines.
During the follow up period on adalimumab ther-
apy, 93.3% (n=180) of enrolled RA patients had con-
comitant anti-rheumatic treatment, the most com-
mon were csDMARDs (n=173; 89.6%) and steroids 
(n=87; 45.1%). Twenty-nine (15%) RA patients had 
non-selective NSAIDs, 11 (5.7%) biological DMARDs, 
10 (5.2%) cox-2 inhibitors, 4 (2.1%) pain killers 
and 5 (2.6%) other drug therapies. The most com-
monly used concomitant drugs were methotrexate 
(n=115; 59.6%), methylprednisolone (n=83; 43%), 
leflunomide (n=59, 30.6%) and sulfasalazine (n=53; 
27.5%). One-hundred and ninety (98.4%) patients 
were treated with 40 mg of adalimumab every other 
week. There were only 2 patients (1%) who were 
administered 40 mg adalimumab every week.
The mean duration of observed adalimumab 
therapy was 48.4 weeks (SD=13.5) in RA. Forty-
Magyar Reumatológia, 2014, 55, 12–24.
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three (22.3%) out of 193 enrolled RA patients dis-
continued the therapy during the study: majority of 
them (27/14%) due to the investigator’s decision, 
12 patients (6.2%) because of lack of efficacy, 8 
patients due to adverse events, 4 patients (2.1%) 
due to the patient’s personal request, whilst 2 and 3 
patients had unknown reasons or other reasons (1% 
and 1.6%, respectively). 43 RA patients who dis-
continued therapy spent an average of 31.8 weeks 
on adalimumab therapy (SD=18.1). 175 (91.1%) RA 
patients were able to use the self-injection and found 
it convenient. Twelve patients (6.3%) were not able 
to self-inject adalimumab because of their disease 
condition. There were 4 patients who could use 
Magyar Reumatológia, 2014, 55, 12–24.
 
RA
N=193
PsA
N=39
AS
N=82
Age (±SD) Mean 53.5 (±12) 50.1(±11.6) 45.5(±13.1)
Female % 84.5% 51.3% 39.0%
Educational background
No professional education n 46 11 17
% 23.8% 28.2% 20.7%
Completed professional education n 117 18 50
% 60.6% 46.2% 61.0%
Education/ apprenticeship n 30 10 13
% 15.5% 25.6% 15.9%
Board-certified university degree or higher n 30 19 50
% 15.5% 48.7% 61.0%
Ongoing professional education (student) n 163 20 32
% 84.5% 51.3% 39.0%
Disease duration (years, ±SD) Mean 8.2(±7.6) 10.2(±9.7) 6.4(±7.1)
Disease activity by DAS28 score
Missing n 9
 NA
% 4.7
Remission (<2.6) n 0
% 0
Low disease activity (2.6 to 3.2) n 1
% 0.5
Moderate disease activity (3.2 to 5.1) n 22
% 11.4
High disease activity (>5.1) n 161
% 83.4
Disease activity by BASDAI
Missing n
 NA
24 3
% 61.5 3.7
BASDAI <4 n 1 5
% 2.6 6.1
BASDAI ≥4 n 14 74
% 35.9 90.2
Functional status by HAQ-DI Mean 1.5 0.9 0.9
NA=not applicable
Table I. Demographic and baseline disease characteristics
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the self-injection but assessed it as 
inconvenient. Regarding the treat-
ment compliance, 93.2% (n=179) 
of RA patients didn’t miss any of 
the injection during the observation 
period. 
With regards to primary effica-
cy endpoints (“positive clinical out-
come”), a DAS28 score decrease 
by at least 1.2 after 3 months was 
observed in 68.7% (n= 114 out of 
166) of RA patients whilst this posi-
tive outcome could not be reached 
only in 11.4% (19/166) of patients. 
33 patients (19.9%) could not be 
evaluated due to lack of data. At 
visit 7, positive clinical outcome was 
achieved by 89% of the patients, 
whereas at the end of the study, 
81.9% of them had positive clinical 
outcome. The mean DAS28 score 
decreased from 6.1 to 2.9 by the 
study end as illustrated in Figure 1. 
At the end of the study 34.3% 
(n=57) of RA patients were in remis-
sion (DAS28<2.6), 21.1% (n=35) 
had low (DAS28 between 2.6 and 
3.2), 28.9% (n=48) had moderate 
(DAS28 between 3.2 and 5.1) and 
15.7% (n=26) had high (DAS28>5.1) 
disease activity. Overall, 47.6% of 
the 166 evaluable patients reached 
the state of remission during the 
observation. Twenty-seven patients 
(16.3%) reached remission at 3 
months, 12% (n=20) between 3 and 
6 months, 15.7% (n=26) between 
6 and 12 months and 3.6% (n=6) 
after 12 months. Fifty-four (32.7%) 
patients did not reach the state 
of low disease activity. Forty-three 
(26.1%) patients reached it at 3 months, thirty-two 
(19.4%) patients between 3 and 6 months, 28 (17%) 
patients between 6 and 12 months and 8 (4.8%) 
patients after 12 months.
The physical function, assessed by HAQ-DI, 
improved during adalimumab therapy. The mean 
HAQ-ID score decreased from 1.6 (SD=0.6) to 1 
(SD=0.7) by the end of the study (see Figure 2). The 
mean change in HAQ-DI was -0.6 (SD=0.6) in RA 
patients at the end of the study compared to the 
baseline (V2).
The mean value of the ESR was 35.7 mm/hour 
(range: 2.0 to 104.0) at visit 1 and 24.2 mm/hour 
(range: 0.0 to 120.0) at the end of the study, whereas 
the mean CRP value decreased from 20.8 mg/l 
(SD=26) at the baseline to 10.9 mg/l (SD=18.4) at the 
end of the study. 
Psoriatic arthritis patients
The total number of PsA patients enrolled in the study 
in Hungary was 40 and 39 were included in SES 
analysis. Of those, 13 patients could be included into 
clinical outcome evaluation analyses. At the study 
end, the number of evaluable PsA patients was 28 
(71.8% of enrolled PsA subjects), corresponding to a 
dropout rate of 20.5% throughout the study. As men-
tioned before, patients with both axial and peripheral 
symptoms could be enrolled. The mean age was 50.1 
years and approximately half of the patients were 
female (51%). Other socio-demographic parameters 
are detailed in Table I. 
The mean disease duration at baseline was 10.2 
(SD=9.7) years representing an established PsA pop-
ulation. Only 2.6% of patients had early disease. At 
baseline, 61.5% (n=24) of PSA patients had severe 
and 38.5% (n=15) moderate disease. Regarding the 
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Number of evaluated patients: V2=166; V3=109; V4=128; V5=129; V6=125; V7=100
Figure 1. The mean value of DAS28 by visit – RA patients, 
as observed
Number of evaluated patients: V2=123; V3=90; V4=88; V5=91; V6=81; V7=72
Figure 2. Mean HAQ-DI by visit- in RA patients, as observed
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activity of axial symptoms, the BASDAI index score 
was ≥4 in 35.9% (n=14) and was <4 in 2.6% (n=1) of 
the patients. There were 24 patients whose baseline 
BADSAI score was not available, most likely due to 
the absence of axial manifestations. 
Prior to the enrollment in the study, 92.3% (n=36) 
of all PsA patients (n=39) received any type of anti-
rheumatic drug treatment. The majority, 71.8% of 
patients (n=28) patients had prior csDMARD therapy, 
28.2% (n=11) non-selective NSAID 23.1% (n=9) 
bDMARD and 10.3% (n=4) steroid treatment. Most 
PsA patients (38.5% of all enrolled PsA subjects) 
received only 1 csDMARD prior to adalimumab 
treatment. During the study, 71.8% (n=28) of PSA 
patients reported concomitant usage of other drugs, 
most of them (n=23, 59%) were on DMARD therapy, 
23.1% (n=9) on non-selective NSAID, 10.3% (n=4) 
on steroid and 5.1% (n=2) on other drug treatment. 
Majority (92.8%) of PsA patients were administered 
40 mg adalimumab every other week. 
The mean duration of patients’ 
adalimumab treatment was 48.2 
weeks (SD=14) in PsA. 8 (20.5%) 
of the 39 patients (100%) discon-
tinued adalimumab treatment prior 
to the study end: 4 (10.3%) patients 
due to the investigator’s decision, 
4 (10.3%) patients due to lack of 
efficacy, 3 (7.7%) patients due to 
adverse event, 1 (2.6%) patient 
due to own personal request and 1 
(2.6%) patient due to other reasons. 
The mean duration of treatment of 
those who discontinued adalimum-
ab therapy was 27.8 weeks (SD= 
15.5 weeks). Most PsA patients 
(97.4%) were able of self-injection 
of adalimumab and found it conve-
nient. Almost all patients had all pre-
scribed injections during the study 
except only one patient (2.6%) who 
missed 3 or more injections.
Regarding the primary endpoint, 
8 (61.5%) of the total 13 evaluable 
PsA patients had positive clinical 
outcome after 3 months of adalim-
umab therapy in the study (defined 
by a 50% or higher decrease in 
BASDAI score relative to baseline), 
whereas at the end of the study 
10 (76.9%) patients had positive 
clinical outcome. The mean BASDAI 
value of PSA patients was 6.3 at 
visit 2 and it decreased to the value 
of 1.5 till Visit 7 (Figure 3) and 
2.4 till the end of the study. Mean 
HAQ-ID score decreased from 1.5 
(SD=0.5) at baseline to 0.9 (SD=0.5) 
at the end of the study and Visit 7 
with mean absolute change of -0.7 
(SD=0.8) (Figure 4).
The mean CRP value was 13.7 mg/l (SD=12.7) 
at the baseline and 7.4 mg/l (SD=11.8) at the end of 
the study. 
Ankylosing spondylitis patients
There were 82 AS patients enrolled in this study with 
mean age of 45.5 (SD 13.1) years and predominant 
male representation. Of those, 73 patients could be 
included into clinical outcome evaluation analyses. At 
the study end, the number of evaluable AS patients 
was 51 (62.2% of enrolled AS subjects), correspond-
ing to a dropout rate of 26.8% throughout the study. 
Additional socio-demographic data are presented in 
Table I. Most of the patients had established disease 
with mean disease duration of 6.4 (SD=7.19) years, 
and 23.2% of early disease (disease duration less 
than 1 year).
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Figure 3. Mean BASDAI value by visits – PsA patients, as observed
Number of evaluated patients: V2=18; V3=14; V4=15; V5=11; V6=11; V7=10
Figure 4. Mean HAQ-DI by visit- in PsA patients, as observed
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Regarding baseline disease activ-
ity, 90.2% (n=74) of the patients 
had high disease activity (BASDAI 
score ≥4) and only 6.1% (n=5) had a 
BASDAI <4, with missing data about 
3.7% (n=3).
As expected, majority (63/82 or 
76.8%) of AS patients received prior 
anti-rheumatic therapy: only approx-
imately a half of patients (n=45; 
54.9%) were treated with prior non-
selective NSAID, and 28% (n=23) 
with DMARDs (23.3% received only 
1 DMARD prior to adalimumab 
treatment). During the study, 67.1% 
(n=55) of the AS patient had con-
comitant medication. Thirty-eight 
patients (46.3%) were treated with 
non-selective NSAIDs, 24.4% (n=20) 
with DMARDs. Vast majority of AS 
patients (96.3% or 79 patients) were 
treated with 40 mg of adalimumab 
every other week and only 2 patients 
(2.4%) received adalimumab on a 
weekly basis.
The mean duration of adalim-
umab treatment was 46.9 weeks 
(SD=14.2). in the analysed AS popu-
lation Twenty-two (26.8%) of the 82 
AS patients discontinued adalimum-
ab treatment during the study: again, 
majority of them (14 patients/7.1%) 
due to the investigator’s decision 7 
patients (8.5%) due to lack of effica-
cy, 4 subjects (4.9%) due to adverse 
events and 4 patients (4.9%) due to 
personal request. The mean duration 
of the treatment of AS patient who 
discontinued adalimumab therapy 
was 27.8 weeks (SD= 11.8 weeks). 
All AS patients were able to self-
inject adalimumab, only two of them (2.5%) assessed 
the process as inconvenient. Similar to RA and PsA 
patients, the compliance was as high as 92.6% with 
95 subjects taking all injection during the observa-
tional period. 
With regards to the primary endpoint, 61.6% 
(n=45) of patients reached primary endpoint after 3 
months. At the end of the study, 50 (68.5%) patients 
had BASDAI 50 response out of 73 evaluable subjects. 
The mean BASDAI score decreased from baseline 7.2 
(SD=1.9) to 2.1 SD=2.1) by Visit 7, corresponding to 
67.1% mean decrease change (SD=29.5) (Figure 5). 
The mean HAQ-ID score was 1.6 (SD=0.6) at baseline 
and 0.8 (SD=0.6) at Visit 7 (Figure 6). 
Regarding inflammatory laboratory parameters, 
mean CRP value decreased from 15.7 mg/l (SD=18) 
at baseline to 6.2 mg/l (SD=10.6) by the end of the 
study. 
Safety
Positive TB screening was documented in 6 patients 
out of all patients who have started adalimumab 
therapy at maximum 31 days before, at or after the 
baseline visit (n=294), all of them received prophylaxis 
according to the local guidelines. It should be noted 
that due to local immunization practices, around half 
of the patients (45.9% of above population) were 
immunized against TB.
In general, adalimumab was well tolerated in the 
routine clinical practice. In total, 101 adverse events 
(AEs) occurred in total of 57 patients correspond-
ing to 18.2% adverse event rate. The majority of 
the events (87.3%) were deemed mild or moder-
ate by the physicians. The rates of adverse events, 
serious adverse events, adverse events leading to 
discontinuation and adverse events of interest are 
presented in Table II. No malignancies, lupus-like 
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Figure 5. Mean BASDAI value by visits – AS patients, as observed
Number of evaluated patients: V2=14; V3=8; V4=9; V5=9; V6=6; V7=5
Figure 6. Mean HAQ-DI by visit- in AS patients, as observed
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syndrome and demyelinating disorder occurred dur-
ing the observation period. For a female RA patient, 
TB immunization was documented at screening visit. 
TB screening at baseline was negative. However, a 
positive TB screening was reported at Visit 6, eleven 
months after start of adalimumab therapy) with 
positive signs of currently active TB in chest X-ray. 
Adalimumab therapy was terminated at Visit 6. There 
was one death, in the AS group: a 63-year-old man 
experienced sudden cardiac death due to acute 
myocardial infarct; this patient had a history of isch-
emic heart disease, cardiac infarct, and right bundle 
branch block. The event was evaluated by the treat-
ing physician as non-related to adalimumab therapy.
The overall adverse event (AE) rate in the RA 
group was 15.5% (out of 193 patients), majority of 
them (66.7%) were deemed as not related to adali-
mumab treatment. The most frequent adalimumab 
related AEs were in the Skin and subcutaneous tissue 
disorders (Alopecia, Drug eruption, Dry skin, Pruritus, 
Skin disorder, Skin reaction and Urticaria) (4.7%), 
Infections and infestations (Asymptomatic bacteriuria, 
Bronchitis, Herpes virus infection, Staphylococcal 
sepsis, Upper respiratory tract infection and Viral 
upper respiratory tract infection) (4.7%) and General 
disorders and administration site condition (Injection 
site reaction, Injection site dermatitis and Edema 
peripheral) (2.1%) system organ classes as coded in 
MedDRA. In the RA group, 5 subjects (2.6%) expe-
rienced any serious events (a total of 9 events): two 
patients had vascular disorder (Hypertension and 
Thrombophlebitis); one patient experienced cardiac 
disorder (Atrial fibrillation), one had gastrointestinal 
disorder (Gastritis erosive), one had nervous sys-
tem disorder (Cerebral ischemia and Paraesthesia), 
another patient suffered a staphylococcal sepsis, 
and one experienced peripheral edema. The overall 
adverse event (AE) rate leading to discontinuation in 
the RA group was 7.8%. 
The adverse event rate in the PsA group was 
higher (25.6%) than in RA (10 out of 39 subjects), 
and majority of the adverse events were deemed 
possibly related to adalimumab treatment (66.7%). 
The most common AEs reported were infections 
(Bronchitis, Pneumonia primary atypical, Sinusitis 
and Urinary tract infection) (12.8%), gastrointestinal 
disorders (Abdominal pain, Vomiting, and Dyspepsia) 
(5.1%) and hepatobiliary disorders (Cholecystitis, 
Cholelithiasis, Hepatic steatosis and Hepatotoxicity) 
(7.7%). During the study, 2 PsA patients suffered 
from serious adverse events: one hepatobiliary disor-
der (Cholecystitis and Cholelithiasis) and one infection 
(Urinary tract infection) were reported. The adverse 
event rate leading to discontinuation in the PsA group 
was 10.3% (4/39), mostly due to infections (5.1%), 
gastrointestinal disorders and hepatobiliary disorders 
(2.6% each).
Approximately one-fifth (20.7%) of the AS patients 
(n=82) experienced any adverse events. However, 
most of the events were deemed as “not related” 
to adalimumab (64.3%). Skin and subcutaneous 
tissue disorders occurred in 4 patients (Erythema, 
Rash and Pruritus) (4.9%), gastrointestinal disorders 
occurred in 4 patients (Diarhhoea, Gastritis ero-
sive, Heamorrhoids and Vomiting) (4.9%), infections 
and infestations (Influenza, Erythema induratum, 
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Adverse event category RA
N=193
PsA
N=39
AS
N=82
Total
N=314
Adverse event 30 (15.5) 10 (25.6) 17 (20.7) 57 (18.2)
Serious adverse event 5 (2.6) 2 (5.1) 1 (1.2) 8 (2.5)
Adverse event leading to discontinuation 15 (7.8) 4 (10.3) 7 (8.5) 26 (8.3)
Infection 9 (4.7) 5 (12.8) 5 (6.1) 19 (6.1)
Serious infection 1 (0.5) 1 (2.6) 0 (0.0) 2 (0.8)
Demyelinating disorder 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Lupus-like syndrome 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Malignancies (excluding lymphoma and NMSC) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
NMSC 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Lymphoma 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Death 0 (0.0) 0 (0.0) 1 (1.2)* 1 (0.3)
Injection site reaction / dermatitis 3 (1.5) 0 (0.0) 0 (0.0) 3 (0.9)
Note: n (%) = number (percentage) of patients with at least one event. A patient could experience more than 1 different term of adverse event
* Sudden cardiac death
Table II. Overview of adverse events
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Pneumonia, Sinusitis and Rhinitis) in 6.1%, nervous 
system disorders occurred both in 2 patients (2.4%, 
Headache and Cerebral ischeamia). As mentioned 
earlier, one patient had serious adverse event in the 
AS group: a fatal acute myocardial infarction result-
ing in sudden cardiac death. Like in the RA and PsA 
group, discontinuation rates due to AEs were less 
than 10%: 8.5% of the AS patients had any adverse 
events leading to discontinuation (skin and subcu-
taneous tissue disorder and infections, in 2 patients 
(2.4%) each).
Discussion
EviraEast was the first and largest real-life data on 
adalimumab assessing clinical outcomes, treatment 
compliance and tolerability of adalimumab in adult 
patients with active rheumatoid arthritis (RA), psori-
atic arthritis (PsA) and ankylosing spondylitis (AS) in 
Hungary in routine clinical practice. As a non-inter-
ventional study, EviraEast included patients that were 
eligible to adalimumab therapy according to the local 
product label and prescription/reimbursement guide-
lines in Hungary. Involved patients were middle aged 
in general, and the gender distribution was consistent 
with the known demographic characteristics of the 
respective diseases, and their characteristics seem 
to be similar to other EU populations. Notably, the 
mean duration of rheumatic disease at the beginning 
of the study was 8.0 years for the total enrolled popu-
lation. Interestingly, both the shortest disease dura-
tion and the highest representation of early disease 
was observed in the AS cohort. Adalimumab initiation 
reflect local practices and access to the medication 
in Hungary, which is to patients with established 
disease and failure to one or multiple conventional 
treatments: due to local prescription and reimburse-
ment regulations, patients with high disease activity 
and nonresponsive to several traditional treatment 
courses were enrolled into the study, therefore this 
population represents a high activity difficult-to-treat 
group.
As expected, most RA and PsA patients received 
multiple csDMARDs previously; the selection of prior 
csDMARDs reflected the local treatment practices 
that are in line with latest local and international treat-
ment recommendations: methotrexate was most 
common in RA, followed by sulfasalazine, leflunomide 
and chloroquine. Almost half of RA patients received 
≥2 prior csDMARDs, while less PsA and AS patients 
received only 1 csDMARD prior to adalimumab, only 
partly reflecting the local treatment and reimburse-
ment guidelines. There were also biologically experi-
enced patients included in the study. By the end of 
study, mean DAS28 score reduced significantly and 
more than half of the RA patients achieved at least 
low disease activity (LDA), and these good results 
may be in part due to the higher use of concomitant 
csDMARDs. According to T2T recommendations, 
LDA is an acceptable treatment goal for longstanding 
RA represented by the majority of the enrolled patient. 
Our data are in line with a recent systematic review 
and meta-analysis of remission rates in randomized 
clinical trials and observational studies showing these 
treatment goals cannot be easily achieved [2]. In 20 
randomized controlled trials, involving 4290 patients 
on either csDMARD monotherapy or combination 
csDMARD therapy, DAS remission occurred in 26% 
of patients on monotherapy and 42% of patients on 
combination therapy. In 17 observational studies, 
including 4762 patients either on DMARD mono-
therapy or DMARD combinations, remission was 
achieved in 27% of the patients, 33% by DAS criteria 
and 17% by ACR criteria [2]. Moreover, in DREAM 
registry that involved mainly long lasting RA patients 
treated with TNF-inhibitors, DAS28 remission was 
achieved by 27% of the patients after 6 months of 
treatment [17]. In a previous observational study with 
adalimumab called ReAct [18] – which was the larg-
est observational study of a TNF-antagonist and was 
designed as an open-label trial to mimic routine care 
of patients with RA – it was found that good EULAR 
response (DAS28 decrease by 1.2) was achieved in 
33% and 56% after 3 months and 1 year, respec-
tively. EULAR response rates were even higher in 
EviraEast at 3 months, most likely because of the 
high baseline disease activity. ReAct also showed 
that adalimumab was also effective when used as 
the second and third TNF antagonist. Similarly, in 
EviraEast, biologic experienced patients were also 
represented in 15.6%; however, no separate analysis 
was done for this biological therapy experienced sub-
population due to small sample size. 
With regards to SpAs, by the study end, the mean 
BASDAI decreased substantially. It should be noted 
again that BASDAI evaluates axial symptoms and the 
percentage of PsA patients achieving a primary end-
point might have been higher if a peripheral measure 
of disease activity had been used These AS results 
are in line with previous results of a multinational 12 
week open label observational study (RHAPSODY) 
conducted with adalimumab reported by Rudwaleit 
et al. [19]. More than half of patients with active 
AS, receiving adalimumab 40 mg every other week 
achieved a BASDAI 50 or ASAS40 response. Similar 
response rates were seen during the first 6 months 
in DANBIO and BSRBR registry [20, 21], where 63% 
and 52% of AS patients treated with TNF-inhibitors 
experienced clinical response (defined as BASDAI 
50% response) during the first 6 months of therapy. 
These data are in line with our observations in this 
study. 
In case of PsA, no observational study with adali-
mumab has assessed the severity of axial symptoms 
so far. Therefore data in this very small patient popu-
lation are valuable, though one must bear in mind 
that lack of assessment of peripheral symptoms in 
PsA population is a major limitation of the study. In 
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the recent ACCLAIM study, the effectiveness and 
safety of adalimumab was evaluated in patients with 
active psoriatic arthritis (PsA) who had inadequately 
responded to prior therapy [22]. Results of this study 
showed that adalimumab-treated patients achieved 
significant improvements in both skin and joint mani-
festations of PsA, as well as in physical function and 
work status. 
Altogether, the clinical outcome results are 
deemed satisfying and consistent with other real-life 
data. 
In EviraEast, physical function was assessed by 
using HAQ-DI in all diagnostic groups and the mean 
HAQ-DI improved substantially. However, employing 
BASFI index in diseases with axial manifestations, i.e. 
in AS and PsA, would have provided more precise 
insight on improvement of physical function. 
Good compliance with the adalimumab admin-
istration schedule meaning no missed injection was 
observed in 93.6% of patients. Regarding drug 
survival, the proportion of discontinued adalimum-
ab therapies ranged from 20.5% in PsA patients, 
through 22.3% in RA patients to 26.8% in AS 
patients. Adalimumab was most frequently dis-
continued due to investigator’s decision (14.3%) 
or lack of efficacy (7.3%), and in 4.8% of patients 
due to adverse events. A premature termination of 
adalimumab therapy occurred on average after 30.2 
weeks of treatment. These data show somewhat 
better compliance and persistence rates compared 
to recently published data [23]: according to the 
systematic literature review, compliance rates with 
biological DMARDs in RA are between 63 and 90%, 
and persistence rates decrease steeply over time. 
According to the data, greater compliance was seen 
with infliximab infusion than with etanercept and 
adalimumab self-administration, because patients 
may miss courses of self-injection whereas intra-
venous administration makes compliance easier to 
control. Interestingly, our data show that treatment 
modalities with self-injection not necessarily lead to 
lower compliance compared to infusion treatments.
In general, adalimumab was well tolerated in this 
study. 14 serious adverse events were reported in 8 
patients (2.5%); 9 (64.3%) of these events were con-
sidered as not related to adalimumab. Sudden car-
diac death occurred in 1 patient with AS. No cases 
of malignancies, lupus-like syndrome, demyelinating 
disorder or tuberculosis were reported, therefore it 
can be concluded that safety in local real-life setting 
is similar to randomized controlled trails, open –label 
extensions and registries with regards to adverse 
event profile and event rates.
In summary, EviraEast PMOS evaluated clinical 
outcomes, safety, treatment compliance and toler-
ability of adalimumab therapy in adult patients with 
active, long-standing RA, PsA and AS in routine 
clinical practice in Hungary. No special demographic, 
disease and disease specific treatment characteris-
tics were observed in the EviraEast patient popula-
tion, as compared with patients generally eligible to 
biologic therapy. The results of the study confirmed 
the well-established effectiveness and safety profile 
of adalimumab in RA, PsA and AS patients treated in 
routine clinical practice. In addition, good tolerability 
and excellent compliance with adalimumab therapy 
were documented.
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